Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $178,511.04 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 7,857 shares of the stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $22.72, for a total value of $178,511.04. Following the transaction, the insider directly owned 549,080 shares of the company’s stock, valued at approximately $12,475,097.60. The trade was a 1.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, August 3rd, Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.92, for a total value of $311,366.64.
• On Friday, July 31st, Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.60, for a total value of $202,224.80.
• On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.81, for a total value of $312,150.00.
• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.96, for a total transaction of $314,400.00.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS opened at $25.06 on Thursday. Kestra Medical Technologies, Ltd. has a twelve month low of $14.10 and a twelve month high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The firm has a 50-day moving average of $22.78 and a two-hundred day moving average of $22.52. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -10.36 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The business had revenue of $28.64 million during the quarter. As a group, analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in shares of Kestra Medical Technologies in the first quarter worth $11,036,000. Woodline Partners LP acquired a new position in Kestra Medical Technologies during the first quarter valued at $2,510,000. Jane Street Group LLC purchased a new stake in Kestra Medical Technologies in the 1st quarter worth about $756,000. Geode Capital Management LLC lifted its stake in Kestra Medical Technologies by 718.5% in the 2nd quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock worth $5,395,000 after acquiring an additional 285,579 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in Kestra Medical Technologies during the 2nd quarter worth about $256,000.

Wall Street Analyst Weigh In

Several research analysts have issued reports on KMTS shares. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. BTIG Research lifted their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Oppenheimer began coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating on the stock. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Finally, The Goldman Sachs Group dropped their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $27.83.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.